Cerner, Baxa sign strategic reseller agreement for DoseEdge Pharmacy Workflow Manager

NewsGuard 100/100 Score

Cerner Corporation (Nasdaq:CERN) and Baxa Corporation have signed a strategic reseller agreement for the Baxa DoseEdge Pharmacy Workflow Manager. The agreement enables Cerner to market and resell the Baxa DoseEdge System as part of an integrated Cerner offering. Cerner clients now have access to a broader suite of solutions and certified integration for dose tracking from compounding to delivery.

"The agreement expands our offering and positions Cerner to continue increasing interoperability across the medication process," says Tom Herzog, Cerner vice president, IT and medical device technologies. Dennis Schneider, Baxa senior VP of marketing and business development, agrees, "Together, the Baxa and Cerner® solutions increase IV room efficiency and advance patient safety. Their interoperability will reduce drug waste and improve communication about patient doses between pharmacy and nursing."

The Cerner partnership will allow health systems to improve their IV room automation by integrating DoseEdge technology with Cerner solutions to create a closed-loop system for medication preparation, management and delivery. DoseEdge connects to the Cerner CareAware® Infusion Management and Cerner Millennium PharmNet® solutions to move critical IV mixing data to the electronic health record.

Cerner and Baxa are exhibiting their solutions at this week's American Society of Health System Pharmacists (ASHP) Midyear Clinical Meeting Dec. 6-8, at the Anaheim Convention Center in Anaheim, California. Baxa and Cerner will work together to assist Cerner clients in their evaluation and implementation of Cerner-integrated DoseEdge. This unique offering of Cerner-integrated DoseEdge is available only from Cerner. Cerner and Baxa have begun work on integration planning, and will communicate further with clients during the first quarter of 2011.

SOURCE Cerner Corporation

Comments

The opinions expressed here are the views of the writer and do not necessarily reflect the views and opinions of News Medical.
Post a new comment
Post

While we only use edited and approved content for Azthena answers, it may on occasions provide incorrect responses. Please confirm any data provided with the related suppliers or authors. We do not provide medical advice, if you search for medical information you must always consult a medical professional before acting on any information provided.

Your questions, but not your email details will be shared with OpenAI and retained for 30 days in accordance with their privacy principles.

Please do not ask questions that use sensitive or confidential information.

Read the full Terms & Conditions.

You might also like...
Common challenges when seeking market access for rare disease therapies